TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01123551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nebulized morphine
Description: After randomization, patients will receive 10 mg of morphine (1ml) diluted in 4 ml normal saline and nebulized with 6 l/mn during 10 min. Nebulization will be repeated systematically 3 times every twenty minutes unless the patient pain was resolved (VAPS 30%). In addition, patients receive a bolus of IV placebo(5 ml normal saline . IV placebo (2 ml) will be repeated every 10 minutes if the objective of analgesia was not reached .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous morphine
Description: After randomization, patients will receive a bolus of 5 mg of IV morphine (5 ml. Then, 2mg of IV morphine (2ml) will be added every 10 minutes if the objective of analgesia was not reached (VAPS \>30%). In addition, normal saline (5ml)is nebulized with 6 l/mn during 10 min and will be repeated systematically every 20 minutes unless the patient's pain was not resolved (VAPS \>30%).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous morphine
Description: After randomization, patients will receive a bolus of 5 mg of IV morphine (5 ml. Then, 2mg of IV morphine (2ml) will be added every 10 minutes if the objective of analgesia was not reached (VAPS \>30%). In addition, normal saline (5ml)is nebulized with 6 l/mn during 10 min and will be repeated systematically every 20 minutes unless the patient's pain was not resolved (VAPS \>30%).
Study: NCT04078646

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention with soy protein isolate
Description: Test meals will be served to the subjects, containing soy protein isolate:~350 mL carrot/tomato juice (50:50, v/v), with 30 g added soy protein, plus 5 ml peanut oil~as morning test meal, served together with 40 g toasted bread and 20 g of cream-cheese plus 10 g margarine.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention with whey protein
Description: Test meals will be served to the subjects, containing soy protein isolate:~350 mL carrot/tomato juice (50:50, v/v), with 30 g added whey protein isolate, plus 5 ml peanut oil~as morning test meal, served together with 40 g toasted bread and 20 g of cream-cheese plus 10 g margarine.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention without protein addition
Description: Test meals will be served to the subjects, containing soy protein isolate:~350 mL carrot/tomato juice (50:50, v/v), plus 5 ml peanut oil~as morning test meal, served together with 40 g toasted bread and 20 g of cream-cheese plus 10 g margarine.
Study: NCT02888678

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Economic Strengthening (Impumelelo)
Description: Economic Strengthening (Impumelelo): This intervention consists of 15 one-hour long sessions on financial education in combination with access to appropriate youth-friendly savings mechanisms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Economic Strengthening (Impumelelo)
Description: Economic Strengthening (Impumelelo): This intervention consists of 15 one-hour long sessions on financial education in combination with access to appropriate youth-friendly savings mechanisms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV Prevention Education (Vhutshilo 2.2)
Description: HIV Prevention Education (Vhutshilo 2.2): This intervention consists of 15 one-hour long sessions that are interactive, skills focused, and cover such topics as expressing one's feelings; dealing with loss and grief; decision-making; coping; gender violence; understanding HIV and other sexually transmitted infections; healthy relationships and staying safe in sexual relationships; and contraception and risks associated with unplanned pregnancy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV Prevention Education (Vhutshilo 2.2)
Description: HIV Prevention Education (Vhutshilo 2.2): This intervention consists of 15 one-hour long sessions that are interactive, skills focused, and cover such topics as expressing one's feelings; dealing with loss and grief; decision-making; coping; gender violence; understanding HIV and other sexually transmitted infections; healthy relationships and staying safe in sexual relationships; and contraception and risks associated with unplanned pregnancy.
Study: NCT04407949

Intervention type: OTHER
Group type: OTHER
Intervention: CPAP Treatment
Description: Comparing events from the CPAP device with the events scored in PSG
Study: NCT03975244

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: Twelve-week of semi-supervised exercise program. The exercise program will combine resistance and endurance training. Both the volume and intensity of training will start at moderate intensity, and progressively be increased at higher volumes and intensities.
Study: NCT01042041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given via transarterial/hepatic chemoembolization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given via transarterial/hepatic chemoembolization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitomycin C
Description: Given via transarterial/hepatic chemoembolization

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transarterial chemoembolization

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hepatic artery embolization
Study: NCT05048511

Intervention type: BIOLOGICAL
Intervention: vitamin D estimation
Description: Serum samples to estimate vitamin D status were collected on the sixth day of stimulation

Intervention type: BIOLOGICAL
Intervention: vitamin D estimation
Description: Serum samples to estimate vitamin D status were collected on the sixth day of stimulation
Study: NCT02864862

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate implant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate implant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate implant

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SCTG

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ADM
Study: NCT03486626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin to increase pregnancy rate in polycystic ovarian syndrome patients
Study: NCT03457064

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PA+Social Adherence Intervention(PASAI)
Description: While both physical activity programs were tailored to match participants' physical needs and abilities, the PA+Social Adherence Intervention(PASAI) introduced elements to promote and strengthen self-efficacy and social interaction among participants.
Study: NCT02706964

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron emission tomography/x-ray computed tomography
Description: A whole-body PET/CT will be performed to identify the site and extent of spread.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging
Description: A brain MRI will be performed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: x-ray computed tomography (CT)
Description: A CT scan will be performed to identify the site and extent of spread.
Study: NCT03976804

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low dose CT scan
Description: Lung cancer screening will be based on the analysis of a low dose CT scan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood sample collection
Description: establish a phenotyping of immunity, blood inflammation and digestive and tumour microbiota

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: faecal sample collection
Description: establish a phenotyping of immunity, blood inflammation and digestive and tumour microbiota
Study: NCT00124046

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Surgery for this diagnosis is a standard of care, as is the medical treatment. We are comparing the two

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Medical Treatment
Description: Surgery for this diagnosis is a standard of care, as is the medical treatment. We are comparing the two
Study: NCT02491814

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Study: NCT04327193

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Titrated PEEP based on driving pressure
Description: Alveolar recruitment and PEEP titration is performed at three time points: after intubation, after Trendelenburg, and after supine after CO2 deflation. The level of PEEP which makes the driving pressure lowest is selected and applied during the operation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional PEEP
Description: Alveolar recruitment is performed at three time points: after intubation, after Trendelenburg, and after supine after CO2 deflation. Conventional PEEP (5cmH2O) is applied during the operation.
Study: NCT02491814

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast cereal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast cereal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast cereal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast cereal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast cereal
Study: NCT02213601

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Study: NCT03569995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 500 mg/m2 + 5%DW 500 mL IVF Begin with 50 mg/hr (increase by 50 mg/hr per 30 min until 400 mg/hr is reached)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 500 mg/m2 + 5%DW 200 mL IV over 15 minutes 3000 mg/m2 + 5%DW 500 mL IVF over 3 hrs Concurrent hydration and subsequent leucovorin rescue is mandatory

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine Injection
Description: 3000 mg/m2 + 5%DW 200 mL IVF over 2 hrs steroid eye drop 0.1%, 2 drops q 6hrs, on days 1-9
Study: NCT01968460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),
Description: Fixed Dose Combination of pramipexole 0.6 mg and rasagiline 0.75 mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg),
Description: Fixed Dose Combination of pramipexole 0.3 mg and rasagiline 0.75 mg once daily
Study: NCT04363372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRx-4DP0004
Description: MRx-4DP0004 is a lyophilised formulation of a proprietary strain of bacteria.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules will be identical in appearance to active product.
Study: NCT01135589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micafungin
Description: i.v.
Study: NCT03644433

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Single layer closure
Description: Uterine incision will be approximated with continuous unlocked suture avoiding the inclusion endometrium and without trimming incision edges.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Double layer closure after resection uterine scar
Description: Uterine incision will be trimmed and old scar tissue will be removed. Then first, endometrium will be approximated by continuous unlocked suture mimicking subcuticular suture avoiding the inclusion of endometrium and second, upper part of myometrium will be approximated by a continuous unlocked suture.
Study: NCT00559507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saracatinib

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02723825

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Closed reduction
Description: Treated with Manipulatio, using plywood, gypsum or external fixation support to fixed

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Closed reduction
Description: Treated with Manipulatio, using plywood, gypsum or external fixation support to fixed

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Open reduction
Description: Open reduction and internal fixation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open reduction
Description: Open reduction and internal fixation
Study: NCT01323205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-40411813
Description: JNJ-40411813 starting dose from 50 to 150 mg according to tolerability dose range increased stepwise from 50 mg to 150 mg capsule by mouth orally. Capsule (s) taken twice daily with a meal for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-40411813
Description: JNJ-40411813 starting dose from 50 to 150 mg as an add-on therapy. Dose is increased step-wise from 50 mg to 150 mg. Capsule(s) taken by mouth twice daily with a meal for 10 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-40411813
Description: JNJ-40411813 starting dose from 50 to 150 mg as an add-on therapy. Dose is increased step-wise from 50 mg to 150 mg. Capsule(s) taken by mouth twice daily with a meal for 10 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsule (s) orally twice daily with a meal for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antipsychotic medication
Description: Regular antipsychotic medications (Risperidone, Olanzapine, Clozapine, Amisulpride, Quetiapine, Paliperidone, Aripiprazole, Haloperidol, Levomepromazine, Zuclopenthixol Hydrochloride, Clotiapine, Pipamperone Hydrochloride, Benperidol, Flupentixol, Fluphenazine Decanoate, Melperone Hydrochloride, or Chlorpromazine Hydrochloride) will be continued in Part B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antipsychotic medication
Description: Regular antipsychotic medications (Risperidone, Olanzapine, Clozapine, Amisulpride, Quetiapine, Paliperidone, Aripiprazole, Haloperidol, Levomepromazine, Zuclopenthixol Hydrochloride, Clotiapine, Pipamperone Hydrochloride, Benperidol, Flupentixol, Fluphenazine Decanoate, Melperone Hydrochloride, or Chlorpromazine Hydrochloride) will be continued in Part B.
Study: NCT01412970

Intervention type: OTHER
Group type: OTHER
Intervention: volume loading
Description: volume loading according to functional parameters of cardiac preload, i.e. stroke volume variations measured by arterial pulse contour analysis
Study: NCT00610142

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pimecrolimus 1% cream
Description: twice a day one fingertip at a 2 times 2 cm2 area of uninvolved skin on the lateral forehead for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrocortison 1% cream
Description: twice a day one fingertip at a 2 times 2 cm2 area of uninvolved skin on the lateral forehead for 4 weeks
Study: NCT00280995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 301012
Description: 100 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 301012
Description: 200 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 301012
Description: 300 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, 36, 43, 50, 57, 64,71, 78, and 85

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 301012
Description: 50 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
Study: NCT01976780

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether Lumefantrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mefloquine
Study: NCT05489601

Intervention type: DRUG
Intervention: Oxycodone
Description: Oxycodone in 5mg increments up to a maximum of 10mg
Study: NCT02623738

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-117 ophthalmic solution low

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-117 ophthalmic solution high

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost ophthalmic solution 0.005%
Study: NCT01882907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vildagliptin
Description: vildagliptin 50mg bid for 16 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone 15mg bid for 16 weeks
Study: NCT04674631

Intervention type: OTHER
Intervention: The effect of neuropathic pain on quality of life, depression and sleep quality
Description: The effect of neuropathic pain on quality of life, depression and sleep quality

Intervention type: OTHER
Intervention: The effect of neuropathic pain on quality of life, depression and sleep quality
Description: The effect of neuropathic pain on quality of life, depression and sleep quality
Study: NCT01396005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: boceprevir
Description: boceprevir 800 mg (4 x 200 mg capsules), orally, every 8 hours, Day 2 through Day 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: boceprevir
Description: boceprevir 800 mg (4 x 200 mg capsules), orally, every 8 hours, Day 2 through Day 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methadone
Description: methadone, 20-150 mg tablets, liquid, or disket, orally, once per day, Day 1 through Day 8
Study: NCT04013061

Intervention type: OTHER
Intervention: Pluridisciplinary consultation
Description: Pharmacist-anesthesiologist team will be present during the anesthetic consultation
Study: NCT01396005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine/naloxone
Description: buprenorphine/naloxone 8/2-24/6 mg, tablets, sublingual, once per day, Day 1 through Day 8
Study: NCT02527044

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fractional Flow Reserve (FFR)
Description: An FFR will be performed pre-operative to the CABG procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional Flow Reserve (FFR)
Description: An FFR will be performed pre-operative to the CABG procedure
Study: NCT00444678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 500 mg/m2, IV every two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m2, IV, q 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 2500 mg, po bid x 7 days every two weeks
Study: NCT01250496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminophylline
Description: 75 mg of intravenous aminophylline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching 0.9 Normal Saline (sterile salt water)administered intravenously.
Study: NCT03007810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay005
Description: Subjects will be randomized into 6 cohorts(10mg, 20mg, 40mg, 80mg, 120mg, 180mg) orally single dose
Study: NCT02653768

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepped Exercise Program
Description: STEP 1: Participants have access to an internet-based exercise program for knee OA.~STEP 2: Participants have access to an internet-based exercise program for knee OA plus telephone support.~STEP 3: Participants have access to an internet-based exercise program for knee OA plus in-person physical therapy visit
Study: NCT03007810

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Subjects will be randomized into 5 cohorts(20mg, 40mg, 80mg, 120mg, 180mg) orally single dose
Study: NCT04495205

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRF under non-eugenol containing periodontal pack
Description: Platelet Rich Fibrin under non-eugenol containing periodontal pack

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-eugenol containing periodontal pack
Description: Non-eugenol containing periodontal pack after gingival depigmentation
Study: NCT02735135

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AIRSOFT DUO for 1 day
Description: The patient is placed on an AIRSOFT DUO mattress for 1 day.
Study: NCT02653768

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Arthritis Education
Description: The arthritis education intervention will include bi-weekly mailings of low-literacy educational materials on a comprehensive set of topics related to OA and its management, based on established treatment guidelines.
Study: NCT04036409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intensive Control of Systolic Blood Pressure (SBP)
Description: Participants in the Intensive arm have a goal of SBP \<120 mm Hg. The use of angiotensin converting enzyme (ACE)-inhibitors/Angiotension receptor blockers (ARBs), Thiazide-type diuretics, calcium channel blockers (CCB), Sustained-release calcium channel blockers (CCBs) will be encouraged, preferably fixed-dose combinations of indapamide + perindopril arginine, perindopril arginine + amlodipine or indapamide + perindopril arginine +amlodipine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard control of Systolic Blood Pressure (SBP)
Description: The same medications used in the Intensive BP arm will be used for the Standard BP arm.
Study: NCT02343471

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 20 g whey protein

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 20 g whey protein
Study: NCT00521846

Intervention type: DEVICE
Intervention: Biomet Explor Modular Radial Head Replacement
Description: As part of the patient's routine care, they will undergo a radial head replacement using the Biomet Explor Modular Radial Head system.
Study: NCT04117776

Intervention type: OTHER
Intervention: Skin microbiological sampling (wash with 2% Chlorhexidine Gluconate)
Description: 3 microbiological samples, per application of agar on skin, after 24h of a first wash with 2% Chlorhexidine Gluconate : 1h before the second wash with the same washing product and then 1 to 2 h after, and 20 to 23h after this second wash.

Intervention type: OTHER
Intervention: Skin microbiological sampling (wash with mild soap)
Description: 3 microbiological samples, per application of agar on skin, after 24h of a first wash with mild soap : 1h before the second wash with the same washing product and then 1 to 2 h after, and 20 to 23h after this second wash.
Study: NCT01496885

Intervention type: OTHER
Intervention: Observational study
Description: This was an observational study and no study drug was administered.